Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by inthnoon Jan 04, 2024 12:11pm
107 Views
Post# 35810648

RE:RE:RE:RE:RE:RE:RE:RE:RE:black out is over, but where's the beef?

RE:RE:RE:RE:RE:RE:RE:RE:RE:black out is over, but where's the beef?
Ok Azzak, let's agree to disagree, You think all is good in onc town and that the pr was good and gives us all something to look forward to and I never said I have the inside track and know it al but you always give CF a pass when he posts everything positive In his opinion and has never been right and leads you all on with misleading information such as
1) The company has an nda and can't release any thing
2) Matt coffey exercised 350.000 options (not true)
3) The private placement was taken by a leading health care professional (it was a hedge fund and we are now down about 50% since just before they came on board.

Ok so moving forward, tell me from the PR what we have that is concrete that for sure we can look forward to in 2024 as there are no timelines, not even one for the panc folfirinox pela trial, none of the goblet trials are continuing to enroll, the company says it has 12 months of cash on hand but that was as of Sept 30th, if this was an update then why not update the cash position rather than give us 3 month old data. What we do know is that onc has said they will move the panc forward supposedly on their own but give no indication on how they are going to do this and at what cost.
<< Previous
Bullboard Posts
Next >>